GlobeNewswire

Informa Markets Launches New Brand Identity

Del

Informa Markets focused on helping specialist markets and communities around the world to trade, innovate and grow

LONDON, April 30, 2019 (GLOBE NEWSWIRE) -- Informa Markets, a division of Informa PLC (LON:INF) formerly known as Informa Exhibitions, today introduced its new name and brand identity and launched a new corporate website, reflecting the ongoing development and expansion of the business and its focus on enabling the success of its customers and the specialist markets in which they work.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

“From Health & Nutrition to Construction, Healthcare & Pharma to Agriculture, Fashion to Hospitality and much more, we live and breathe specialist markets,” said Charlie McCurdy, CEO of Informa Markets. “Informa Markets really brings to life the role we play helping to bring energy, opportunity, growth and success to the specialist markets our customers operate in, and to our customers’ businesses.”

He continued: “The new Informa Markets identity reflects the continued expansion of our services both at exhibitions and beyond the show floor, into data and digital products and specialist content, as well as the expansion of our own business. After combining with UBM’s powerful event-focused brands in 2018, Informa Markets is a single, strong identity that brings together all our teams, partners and customers across our increasingly broad and international portfolio.”

Informa Markets is the leading global platform for industries, specialist markets and communities to trade, grow and engage. It consists of more than 550 international B2B events and brands, as well as specialist digital content and data solutions, with over 4,400 colleagues based in more than 40 countries around the globe. Informa Markets provides customers with meaningful experiences where they can engage, experience and do business, helping global communities to thrive 365 days a year.

“Similar to how people and companies evolve, so has our brand identity,” said Richard Brook, Executive Vice President, Marketing, Informa Markets. “It has progressed over the years as we have produced impactful events, brands, digital offerings, a distinctive culture and engaged communities around the globe. The new Informa Markets identity is a fantastic representation of what and who we are today, and how that will develop in the future as we continue to advance and provide platforms that facilitate connections and the best customer experience.”

To explore the new branding and website visit www.InformaMarkets.com.

About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals to Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.

Contact Information
Ashley Womack
Director of External Communications, Informa Markets
Ashley.C.Womack@informa.com 
415-307-4858

A video accompanying this release is available at https://youtu.be/jSkp5O5NSps

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CESTPressemelding

New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus

Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CESTPressemelding

ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r

Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CESTPressemelding

American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and

XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa23.5.2019 14:20:00 CESTPressemelding

AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019. The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS. XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, whi

LGC CAPITAL Announces Results of Annual Meeting, Appointment of New Chairman and Approval of Name Change to Elixxer Ltd.23.5.2019 14:00:00 CESTPressemelding

MONTRÉAL, May 23, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held yesterday in Montreal, Quebec. At the Meeting, all five of the nominees listed in the Corporation’s management information circular dated April 17, 2019 were elected as directors, all with a vote of more than 92% of the shares voted in their favour. Accordingly, the directors of LGC for the ensuing year are Mohammed Ghafari, Mazen Haddad, Rafi Hazan, David Lenigas and Ferras Zalt. At the Meeting, shareholders adopted a special resolution approving a change in the name of the Corporation to “Elixxer Ltd.” or such other name as the Corporation’s directors may determine. The special resolution was supported by 98.94% of the votes cast at the Meeting. The Corporation intends to proceed with the name change as expeditiously as possible. Shareholders also adopted: a special

Merus Announces 2019 Annual General Meeting of Shareholders23.5.2019 14:00:00 CESTPressemelding

UTRECHT, The Netherlands, May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting of Shareholders will be held on June 12, 2019 at 1:00 pm (CEST) at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clin